Health
Super-backed company develops COVID treatment – Financial Standard
A biotech company backed by AustralianSuper, HESTA, Hostplus and Statewide Super has developed a new preventative treatment shown to reduce COVID-19 levels by u…
A biotech company backed by AustralianSuper, HESTA, Hostplus and Statewide Super has developed a new preventative treatment shown to reduce COVID-19 levels by up to 96%.
The product, INNA-051, is being developed by Ena Respiratory, and works by stimulating and boosting the innate immune system. The study found that boosting the immune system this way limits the ability of the COVID-19 virus to infect the animals used in the study.
Ena Respiratory raised $11.7 million from a coalition of instit…
-
Business16 hours agoIAG shares are racing higher today. Here’s why
-
Noosa News13 hours agoProp Allan Alaalatoa returns to the Wallabies line-up for Rugby Championship game against Argentina
-
General17 hours agoQueensland government dumps Forest Wind project
-
Noosa News17 hours agoLifeFlight airlifts man after boat runs aground